Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study

Table 4 Change in total cholesterol, triglyceride, and HDL cholesterol in 72 patients treated with Alirocumab or Evolocumab

		Alirocumab 75 mg (n = 25) Follow up length median 24 weeks			Alirocumab 150 mg (n = 15) Follow up length median 26 weeks			Evolocumab 140 mg (n = 32) Follow up length median 24 weeks
Variable measured		percentile			percentile			percentile
		25^th	50^th	75^th	25^th	50^th	75^th	25^th	50^th	75^th
Total cholesterol	Entry (mg/dl)	172	192	231	227	259	294	222	252	299
	Follow up (mg/dl)	118	155	177	114	145	181	117	157	203
	Absolute change (mg/dl)	−25	−76	−94	−83	−105	−168	−65	−86	−139
	P (paired Wilcoxon)	p <.0001			p <.0001			p <.0001
	Percent change (%)	−14	−32	−45	−34	−48	−53	−26	−39	−52
	P (Wilcoxon)	p <.0001			p <.0001			p <.0001
Triglyceride	Entry (mg/dl)	96	135	173	124	160	317	101	145	167
	Follow up (mg/dl)	80	106	154	76	105	161	80	106	142
	Absolute change (mg/dl)	+3	−29	−57	−10	−51	−102	+4	−25	−52
	P (paired Wilcoxon)	p = .0051			p = .0015			p = .0069
	Percent change (%)	+3	−21	−33	−12	−32	−41	+4	−23	−35
	P (Wilcoxon)	p = .0097			p = .0015			p = .0092
HDL cholesterol	Entry (mg/dl)	41	53	61	40	51	57	45	56	68
	Follow up (mg/dl)	40	51	65	44	52	65	47	58	75
	Absolute change (mg/dl)	−1	+2	+5	+1	+7	+10	0	+4	+14
	P (paired Wilcoxon)	p = .070			p = .0075			p = .0028
	Percent change (%)	−2	+5	+11	+3	+11	+17	0	+8	+21
	P (Wilcoxon)	p = .092			p = .010			p = .0029

ISSN: 1476-511X